Bioventix plc
(“Bioventix” or “the Company”)
Notice of Results and Notice of AGM
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it will release its preliminary results for the year ended 30 June 2018 on 8 October 2018.
The Company’s Annual General Meeting will be held on Thursday 6 December at 2.00p.m at Farnham Castle, Castle Street, Farnham, Surrey, GU9 0AG.
TR-1: Notification of major interest in shares.
TR-1: Notification of major interest in shares. (more…)
Unaudited interim results for the six months ended 31st December 2017. (more…)
TR-1: Notification of major interest in shares. (more…)
Bioventix plc
(“Bioventix” or the “Company”)
Result of AGM
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed.
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 19 October 2017 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”)
(more…)
TR-1: Notification of major interest in shares. (more…)
TR-1: Notification of major interest in shares. (more…)